Buy or sell guide
Should I Buy ABT Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Abbott Laboratories.
Updated 2026-06-21
Wall Street currently rates ABT buy with a 12-month price target of $127 (+44.2% upside). The sections below cover the bull case, key risks, and latest earnings context for ABT.
Wall Street
Buy41 analystsConsensus target
$127 target (+44.2%)Current price $88.38Analyst sentiment
No recent analyst posts capturedWaiting for fresh postsEarnings context
EPS beat 0.9%Reported Thu Apr 16Wall Street verdict
Should I Buy ABT Stock? Here's What Analysts Think
41 analysts currently cover ABT. Below is their consensus rating, price target range, and implied upside.
According to 41 analysts, Abbott Laboratories (ABT) is rated Buy with a consensus 12-month price target of $127 — representing 44% upside from today's price of $88. The bull case target is $152, the bear case is $92.
ABTBuy
From 41 analyst ratings- Current price
- $88.38
- Consensus Target
- $127 (+44.2% upside)
- Forward P/E
- 16.1x
- Coverage
- 41 analyst ratings
High target$152
Low target$92
At $88.38, the consensus setup implies +44.2% versus the 12-month target.
- 31 of 41 analysts lean Buy or Strong Buy, while 10 stay on Hold and 0 lean bearish.
- ABT trades at roughly 16.1x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $92 to $152, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for ABT right now.
Analyst ratings update weekly. Get ABT's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Live commentary on X
What Analysts Are Saying About Abbott Laboratories Right Now
Real posts from high-reach stock analysts mentioning ABT, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about ABT in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy ABT?
Is ABT a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for ABT before you decide whether to buy, hold, or sell.
Current setup
ABT beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Acquisition IntegrationThe successful integration of Exact Sciences is expected to significantly boost Abbott's diagnostics business and overall growth trajectory.
- Mid-Teens Growth in CologuardAnalysts project mid-teens growth for Cologuard, supported by a substantial addressable market.
- Favorable Feedback on New ProductsNew electrophysiology products like Volt PFA and TactiFlex Duo are receiving extremely favorable physician feedback, indicating potential for accelerated growth.
- Consistent Double-Digit GrowthThe medical device segment is experiencing consistent double-digit growth, contributing positively to overall performance.
- Positive Analyst RatingsAnalysts maintain a 'Buy' or 'Outperform' rating on ABT, with a median price target around $120, indicating significant upside.
- Potential Fair Value of $168If the Exact Sciences integration is smooth, forecasts suggest a potential fair value of $168 due to quicker EPS accretion.
Wall Street rates ABT buy, giving the bull case institutional backing from 41 analysts.
Watch Out For
What can break the setup quickly
- Nutrition Segment DeclinesThe Nutrition segment has faced declines due to incomplete pricing pass-through at retail, posing a risk to revenue.
- EPS Dilution from AcquisitionThe Exact Sciences acquisition is expected to dilute EPS, impacting earnings through 2026 and 2027 before becoming accretive.
- Litigation RisksAbbott faces litigation risks, including a recent $70 million jury award related to infant formula safety, with hundreds of similar cases pending.
- Execution Challenges in Heart MarketThere are noted execution challenges in the structural heart market, along with competitive share losses that could hinder growth.
- Bear Case Fair Value of $100Some analysts project a bear case fair value of $100, assuming below-guidance EPS due to unforeseen headwinds.
- Operational Complexity RisksOperational complexity could hinder the business, especially if key growth drivers like CGM or Cologuard falter.
Watch whether new negative commentary on ABT points to these structural risks or is simply reacting to short-term price moves.
ABT Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $1.15 vs $1.14 est.Beat 0.9%
- Revenue
- $11.2B vs $11.0B est.Beat 1.5%
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into ABT consensus models and risk factors.
View Analysis
Should I Buy ABT?
Wall Street verdict, signals, and target summaries.
See Verdict
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ABT — Frequently Asked Questions
Quick answers to the most common questions about buying ABT stock.
Should I buy ABT stock right now?
Verdict
ABT looks attractive at current levels — Wall Street's consensus rating is "Buy" with a $127 price target (+44.2% upside from $88.38). This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy ABT?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +44.2% upside to the $127 target.
What is the price target for ABT stock?
Price Target
ABT's consensus 12-month price target is $127, set by 41 Wall Street analysts. The bull case high is $152 and the bear case low is $92. From the current price of $88.38, this implies +44.2% upside.
Is ABT overvalued or undervalued?
Valuation
ABT appears undervalued — the $127 consensus target is +44.2% above today's $88.38. It trades at a forward P/E of 16.1x. Targets range from $92 (bear) to $152 (bull), reflecting different assumptions about growth and margins.
Should I buy ABT before earnings?
Earnings
ABT reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $127 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about ABT stock?
Coverage
Of 41 analysts covering Abbott Laboratories (ABT): 0 Strong Buy, 31 Buy, 10 Hold, 0 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $127 (range $92–$152). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying ABT stock?
Risks
No analyst currently rates ABT a Sell, but the 10 Hold ratings reflect concerns about valuation, execution risk, or near-term catalysts. See the Bull vs. Risk cards above for the specific theses on Abbott Laboratories.
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.